Sector News

J&J completes acquisition of Alios Biopharma

November 12, 2014
Life sciences
Johnson & Johnson (J&J) announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
 
With this acquisition complete, Alios BioPharma will now become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The acquisition includes Alios BioPharma’s portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy currently in phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).  RSV is the last of the major paediatric diseases that currently has no effective therapy.  The acquisition also includes two early-stage compounds for hepatitis C (HCV) that could potentially augment Janssen’s existing HCV portfolio.
 
“The acquisition of Alios BioPharma further reflects our commitment to bringing together the best science from around the globe to address significant unmet need.   Together we will further strengthen Janssen’s infectious diseases pipeline to address the needs of patients and families affected by some of the world’s most devastating diseases,” said Paul Stoffels, M.D., chief scientific officer of Johnson & Johnson and Worldwide chairman, pharmaceuticals.
 
Source: pharmabiz

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”